[CAS NO. 1895050-66-4] 6RK73
PRODUCTS SPECIFICATIONS [1895050-66-4]
DESCRIPTION [1895050-66-4]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 307.37 |
| Molecular Formula | C13H17N5O2S |
| SMILES | O=C([C@@H]1CN(C#N)CC1)NC2=NC=C(N3CCOCC3)S2 |
1 Publications Citing Use of MCE
Summary
IC50 & Target
IC50: 0.23 µM (UCHL1), 236 µM (UCHL3) [1]
In Vitro
6RK73 (5 µM; 1-3 hours) treatment displays strong inhibition of the TGFβ-induced pSMAD2 and pSMAD3, and a decrease of TβRI and total SMAD protein levels in MDA-MB-436 cells
[1]
.
6RK73(5 µM; 24-48 hours) results migration significantly slower than the DMSO control group in MDA-MB-436 cells
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | MDA-MB-436 cells |
| Concentration: | 5 µM |
| Incubation Time: | 24, 48 hours |
| Result: | Migrated significantly slower than the DMSO control group |
Western Blot Analysis [1]
| Cell Line: | MDA-MB-436 cells |
| Concentration: | 5 µM |
| Incubation Time: | 1, 2, 3 hours |
| Result: | Displayed strong inhibition of the TGFβ-induced pSMAD2 and pSMAD3, and a decrease of TβRI and total SMAD protein levels. |
In Vivo
6RK73 displays a potent inhibition of breast cancer extravasation in zebrafish [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 125 mg/mL ( 406.68 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.2534 mL | 16.2670 mL | 32.5341 mL |
| 5 mM | 0.6507 mL | 3.2534 mL | 6.5068 mL |
| 10 mM | 0.3253 mL | 1.6267 mL | 3.2534 mL |